194 related articles for article (PubMed ID: 27500989)
1. Regorafenib induced severe toxic hepatitis: characterization and discussion.
Sacré A; Lanthier N; Dano H; Aydin S; Leggenhager D; Weber A; Dekairelle AF; De Cuyper A; Gala JL; Humblet Y; Sempoux C; Van den Eynde M
Liver Int; 2016 Nov; 36(11):1590-1594. PubMed ID: 27500989
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities.
Taguchi D; Inoue M; Fukuda K; Yoshida T; Shimazu K; Fujita K; Okuyama H; Matsuhashi N; Tsuji A; Yoshida K; Miura M; Shibata H
Int J Clin Oncol; 2020 Apr; 25(4):531-540. PubMed ID: 31807967
[TBL] [Abstract][Full Text] [Related]
3. Clinical Features of Regorafenib-induced Liver Injury in Japanese Patients From Postmarketing Experience.
Uetake H; Sugihara K; Muro K; Sunaya T; Horiuchi-Yamamoto Y; Takikawa H
Clin Colorectal Cancer; 2018 Mar; 17(1):e49-e58. PubMed ID: 29074353
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
Sueda T; Sakai D; Kudo T; Sugiura T; Takahashi H; Haraguchi N; Nishimura J; Hata T; Hayashi T; Mizushima T; Doki Y; Mori M; Satoh T
Anticancer Res; 2016 Aug; 36(8):4299-306. PubMed ID: 27466548
[TBL] [Abstract][Full Text] [Related]
5. Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer.
Kobayashi K; Kawakami K; Yokokawa T; Aoyama T; Suzuki K; Wakatsuki T; Suenaga M; Sato H; Sugiyama E; Yamaguchi K; Hama T
Oncology; 2019; 96(4):200-206. PubMed ID: 30763946
[TBL] [Abstract][Full Text] [Related]
6. Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan.
Hirano G; Makiyama A; Makiyama C; Esaki T; Oda H; Uchino K; Komoda M; Tanaka R; Matsushita Y; Mitsugi K; Shibata Y; Kumagai H; Arita S; Ariyama H; Kusaba H; Akashi K; Baba E
Anticancer Res; 2015 Jan; 35(1):371-7. PubMed ID: 25550574
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer.
Fukuoka S; Shitara K; Noguchi M; Kawazoe A; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
Clin Colorectal Cancer; 2017 Jun; 16(2):e39-e44. PubMed ID: 27780748
[TBL] [Abstract][Full Text] [Related]
8. Adverse event management strategies: optimizing treatment with regorafenib in patients with metastatic colorectal cancer.
Mitchell J; Khoukaz T; McNeal D; Brent L
Clin J Oncol Nurs; 2014 Apr; 18(2):E19-25. PubMed ID: 24675266
[TBL] [Abstract][Full Text] [Related]
9. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands.
Nonomiya Y; Yokokawa T; Kawakami K; Kobayashi K; Aoyama T; Takiguchi T; Sugisaki T; Suzuki K; Suenaga M; Wakatsuki T; Yamaguchi K; Sugimoto Y; Hama T
Oncol Res; 2019 May; 27(5):551-556. PubMed ID: 29914591
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402).
Tanioka H; Miyamoto Y; Tsuji A; Asayama M; Shiraishi T; Yuki S; Kotaka M; Makiyama A; Shimokawa M; Shimose T; Masuda S; Yamaguchi T; Komatsu Y; Saeki H; Emi Y; Baba H; Oki E; Maehara Y;
Oncology; 2018; 94(5):289-296. PubMed ID: 29514163
[TBL] [Abstract][Full Text] [Related]
12. Regorafenib. Metastatic colorectal cancer in treatment failure: may prolong survival by a few weeks.
Prescrire Int; 2014 Jan; 23(145):8-11. PubMed ID: 24516902
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular assessment of regorafenib monotherapy.
Kakizawa N; Suzuki K; Fukui T; Takayama Y; Ichida K; Muto Y; Hasegawa F; Watanabe F; Kikugawa R; Tsujinaka S; Futsuhara K; Miyakura Y; Noda H; Rikiyama T
Oncol Rep; 2017 Apr; 37(4):2506-2512. PubMed ID: 28259999
[TBL] [Abstract][Full Text] [Related]
14. [Tolerability and efficacy of regorafenib in patients with unresectable metastatic colorectal cancer].
Tanaka A; Sadahiro S; Suzuki T; Okada K; Saito G
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1231-6. PubMed ID: 25335705
[TBL] [Abstract][Full Text] [Related]
15. Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events.
Hofheinz RD; Arnold D; Kubicka S; Prasnikar N; Vogel A
Oncol Res Treat; 2015; 38(6):300-8. PubMed ID: 26045027
[TBL] [Abstract][Full Text] [Related]
16. [Regorafenib in patients with metastatic colorectal cancer: a review and an update].
Zaniboni A; Mansueto G
Recenti Prog Med; 2015 Dec; 106(12):629-33. PubMed ID: 26780072
[TBL] [Abstract][Full Text] [Related]
17. Regorafenib-induced retinal and gastrointestinal hemorrhage in a metastatic colorectal cancer patient with liver dysfunction: A case report.
Tsuchihashi K; Shimokawa H; Takayoshi K; Nio K; Aikawa T; Matsushita Y; Wada I; Arita S; Ariyama H; Kusaba H; Sonoda KH; Akashi K; Baba E
Medicine (Baltimore); 2017 Oct; 96(42):e8285. PubMed ID: 29049226
[TBL] [Abstract][Full Text] [Related]
18. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.
Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM
Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491
[No Abstract] [Full Text] [Related]
19. Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis.
Giampieri R; Prete MD; Prochilo T; Puzzoni M; Pusceddu V; Pani F; Maccaroni E; Mascia R; Baleani MG; Meletani T; Berardi R; Lanzillo AM; Mariotti S; Zaniboni A; Cascinu S; Scartozzi M
Sci Rep; 2017 Apr; 7():45703. PubMed ID: 28378839
[TBL] [Abstract][Full Text] [Related]
20. Unexpected side effect in mCRC: A care-compliant case report of regorafenib-induced hyperammonemic encephalopathy.
Quirino M; Rossi S; Schinzari G; Basso M; Strippoli A; Cassano A; Barone C
Medicine (Baltimore); 2017 Apr; 96(16):e6522. PubMed ID: 28422839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]